Drug intelligence / Profile preview

Rubavax-M

Development stage: Unknown
Lead developer: Incepta Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Rubavax-M is a live, attenuated combination vaccine developed and marketed by Incepta Vaccines for the prevention of measles and rubella. It contains the Long-47 strain of the measles virus (grown in chicken embryo cell cultures) and the RA27/3 strain of the rubella virus (grown in human diploid cells). The vaccine is indicated for active immunization in individuals older than 8 months to induce protective immunity against both measles (rubeola) and rubella (German measles). It is administered as a single 0.5 ml dose via deep subcutaneous injection and is a key component of the immunization program in Bangladesh.

Brand names: Rubavax-M
Other names: Rubavax MMeasles and Rubella Vaccine (Live) USP

Beyond the preview

Go deeper on Rubavax-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rubavax-M.

Explore the full profile